Streetbeat News

XRTX

XORTX Therapeutics Inc.

https://www.xortx.com

Industry

Biotechnology

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Open

1.32

Mkt cap

4.8M

Volume

7.8K

High

1.39

P/E Ratio

-3.48

52-wk high

7.00

Low

1.25

Div yield

N/A

52-wk low

1.09

Alliance Global Partners analyst James Molloy has reaffirmed a Buy rating on XORTX Therapeutics (NASDAQ:XRTX) and increased the price target from $9 to $14, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:09 pm

Titan Machinery Inc. (TITN) shares dropped by 8.1% to $23.41 due to weaker-than-expected quarterly earnings and sales. The company reported earnings of $1.32 per share, missing estimates of $1.53 per share, and sales of $694.12 million, below the expected $727.20 million. Other stocks experienced significant movements in Thursday's mid-day session, with notable gainers and losers across various sectors.

Portfolio Pulse from Lisa Levin

November 30, 2023 | 6:13 pm

XORTX Therapeutics has announced a 1-for-9 share consolidation, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 7:19 pm

XORTX Therapeutics Inc. has announced a 1-for-9 share consolidation, reducing the number of issued and outstanding shares from 17,989,687 to approximately 1,998,854. The consolidation has been approved by the TSX Venture Exchange and will be effective from November 9, 2023. The shares will continue to trade on the TSXV and the Nasdaq Capital Market under the symbol 'XRTX'.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 10:54 pm

The article lists the stocks that have gained and lost the most in Tuesday's mid-day session. Some of the top gainers include InMed Pharmaceuticals, LianBio, Ascent Solar Technologies, and Falcon's Beyond Global. On the other hand, reAlpha Tech Corp, LumiraDx Limited, INVO Bioscience, and Markforged Holding Corporation were among the biggest losers.

Portfolio Pulse from Lisa Levin

October 24, 2023 | 6:12 pm

Several stocks are experiencing significant pre-market trading movements. AERWINS Technologies Inc. (AWIN), Ascent Solar Technologies, Inc. (ASTI), WiSA Technologies, Inc. (WISA), Lytus Technologies Holdings PTV. Ltd. (LYT), LM Funding America, Inc. (LMFA), Soluna Holdings, Inc. (SLNH), Organovo Holdings, Inc. (ONVO), Argo Blockchain plc (ARBK), CleanSpark, Inc. (CLSK), and Logitech International S.A. (LOGI) are among the gainers. LumiraDx Limited (LMDX), Markforged Holding Corporation (MKFG), XORTX Therapeutics Inc. (XRTX), TC Biopharm (Holdings) Plc (TCBP), IonQ, Inc. (IONQ), The Alkaline Water Company Inc. (WTER), SeaStar Medical Holding Corporation (ICU), Alaunos Therapeutics, Inc. (TCRT), Harpoon Therapeutics, Inc. (HARP), and INVO Bioscience, Inc. (INVO) are among the losers.

Portfolio Pulse from Lisa Levin

October 24, 2023 | 11:31 am

US stocks traded lower with the Dow Jones index falling over 100 points. The Chicago Fed National Activity Index increased to +0.02 in September from -0.22 in the prior month. LumiraDx Limited, INVO Bioscience, and Akumin Inc. saw their shares rise after various strategic collaborations and agreements. Li-Cycle Holdings Corp., Revolution Medicines, and XORTX Therapeutics saw their shares drop due to halted projects and clinical trial data.

Portfolio Pulse from Lisa Levin

October 23, 2023 | 1:43 pm

The article lists the top gainers and losers in pre-market trading. LumiraDx Limited's shares surged after a strategic collaboration with AstraZeneca and Everton. Akumin Inc. rose after an agreement with Stonepeak to go private. Textainer Group Holdings Limited gained after agreeing to be acquired by Stonepeak. Harpoon Therapeutics, Inc. climbed after disclosing updated interim data from a clinical trial. Roivant Sciences Ltd. rose after Roche agreed to acquire Telavant. Troika Media Group, Inc. fell after reporting financial results. XORTX Therapeutics Inc. dipped after a significant jump on Friday.

Portfolio Pulse from Lisa Levin

October 23, 2023 | 11:32 am

The article lists the stocks that gained and lost the most in Friday's mid-day session. Among the gainers were XORTX Therapeutics, Lipella Pharmaceuticals, and Catalyst Biosciences, while the losers included WEBUY GLOBAL, SolarEdge Technologies, and Processa Pharmaceuticals. Factors influencing these movements include FDA clearances, strategic appointments, acquisitions, and financial results.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 5:45 pm

Shares of Xortx Therapeutics Inc. (NASDAQ:XRTX) are trading higher on unusually heavy trading volume, despite no company-specific news. Over 45 million shares have been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares. The company's shares are up 52% at 53 cents at the time of publication.

Portfolio Pulse from Erica Kollmann

October 20, 2023 | 3:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.